Target Poor or Non Binder(s) Information
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T62974 | Target Info | |||
| Target Name | Somatostatin receptor type 4 (SSTR4) | ||||
| Synonyms |
SSTR4; SS4R
Click to Show/Hide
|
||||
| Target Type | Clinical trial Target | ||||
| Gene Name | SSTR4 | ||||
| Biochemical Class | GPCR rhodopsin | ||||
| UniProt ID | |||||
| Poor Binders of This Target (in total, 4 binders) | Download | Top | |||
|---|---|---|---|---|---|
| Compound Name |
6-Chloro-3-(4-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)quinoline
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL468176; BDBM50261729
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 50000 nM
|
[1] | |||
| Compound Name |
3-(4-Piperidinophenyl)-1-[3-[(5-bromo-2-pyridinyl)(3,4-dichlorobenzyl)amino]propyl]thiourea
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL143539; BDBM50068038
Click to Show/Hide
|
||||
| Activity |
Ki = 71000 nM
|
[2] | |||
| Compound Name |
3-(3-Phenylpropyl)-1-[4-[(2-pyridinyl)(4-bromobenzyl)amino]butyl]thiourea
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL142811; BDBM50068048; 1-{4-[(4-Bromo-benzyl)-pyridin-2-yl-amino]-butyl}-3-(3-phenyl-propyl)-thiourea
Click to Show/Hide
|
||||
| Activity |
Ki = 71000 nM
|
[2] | |||
| Compound Name |
(1R,3R)-3-(4-(5-Fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1-ethyl-pyrazol-4-yl)-1-(3-methyl-1,3,4-oxadiazol-3H-2-one-5-yl)-2,3,4,9-tetrahydro-1H-ss-carboline
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL3582336; MK-1421; BDBM50091414
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 100000 nM
|
[3] | |||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4267-74. | ||||
| REF 2 | Nonpeptide somatostatin agonists with sst4 selectivity: synthesis and structure-activity relationships of thioureas. J Med Chem. 1998 Nov 19;41(24):4693-705. | ||||
| REF 3 | Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes. ACS Med Chem Lett. 2015 Mar 18;6(5):513-7. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.